Skip to main content

Table 2 Clinical characteristics of respondents with PsA, stratified by time between seeking medical attention and receiving formal diagnosis

From: Patient perspectives on the pathway to psoriatic arthritis diagnosis: results from a web-based survey of patients in the United States

CharacteristicsTotal Respondents
(N = 203)
<  6 Months
(n = 69)
6 Months to 4 Years
(n = 68)
≥ 5 Years
(n = 66)
P Value
RAPID3 cumulative score (0–30)
 Mean (SD)14.7 (5.8)14.3 (6.5)14.5 (5.8)15.4 (5.0)0.559
 Median (IQR)15.5 (8.5)14.5 (10.2)15.5 (8.9)16.3 (6.0) 
 Range1.3–29.01.3–29.02.0–24.32.0–25.2 
RAPID3 disease severity category, n (%)    0.688
 Near remission (1–3)5 (2.5)2 (2.9)2 (2.9)1 (1.5) 
 Low (4–6)14 (6.9)6 (8.7)5 (7.4)3 (4.5) 
 Medium (7–12)45 (22.2)18 (26.1)16 (23.5)11 (16.7) 
 High (13–30)139 (68.5)43 (62.3)45 (66.2)51 (77.3) 
Years since first symptom experienced
 Mean (SD)a15.1 (11.8)13.4 (13.2)10.7 (7.6)21.3 (11.5)< 0.001
 Median (IQR)12.0 (13.0)8.0 (13.0)9.0 (10.0)18.0 (18.0) 
 Range0–60.00–60.01.0–39.03.0–52.0 
Years since official diagnosis
 Mean (SD)8.7 (9.6)10.8 (12.4)8.1 (7.3)7.3 (7.9)0.073
 Median (IQR)6.0 (10.0)7.0 (11.0)6.5 (9.0)5.0 (8.0) 
 Range0–60.00–60.00–39.00–42.0 
Extent of psoriasis (assessed by area covered in number of palms), n (%)b    0.259
 Little to no psoriasis (< 1 palm)105 (51.7)33 (47.8)43 (63.2)29 (43.9) 
 Only a few patches (1–2 palms)45 (22.2)14 (20.3)12 (17.6)19 (28.8) 
 Scattered patches (3–10 palms)41 (20.2)17 (24.6)9 (13.2)15 (22.7) 
 Extensive psoriasis (> 10 palms)12 (5.9)5 (7.2)4 (5.9)3 (4.5) 
Current symptoms (in ≥ 50% of respondents), n (%)c
 Joint pain176 (86.7)57 (82.6)61 (89.7)58 (87.9)0.498
 Fatigue169 (83.3)56 (81.2)57 (83.8)56 (84.8)0.867
 Stiffness159 (78.3)53 (76.8)51 (75.0)55 (83.3)0.456
 Swollen joints127 (62.6)42 (60.9)45 (66.2)40 (60.6)0.759
 Reduced range of motion in the joints of the arms and legs122 (60.1)43 (62.3)38 (55.9)41 (62.1)0.679
 Back pain119 (58.6)39 (56.5)37 (54.4)43 (65.2)0.414
 Foot problems115 (56.7)34 (49.3)37 (54.4)44 (66.7)0.115
 Tendon or ligament paina109 (53.7)27 (39.1)37 (54.4)45 (68.2)0.003
 Difficulty walking108 (53.2)39 (56.5)33 (48.5)36 (54.5)0.615
 Reduced range of motion in spine and/or hips107 (52.7)34 (49.3)34 (50.0)39 (59.1)0.459
Other health conditions (in ≥ 25% of respondents), n (%)c
 Depression126 (62.1)35 (55.1)49 (72.1)39 (59.1)0.105
 Anxiety118 (58.1)38 (55.1)40 (58.8)40 (60.6)0.806
 Hypertension97 (47.8)39 (56.5)28 (41.2)30 (45.5)0.178
 Migraines90 (44.3)24 (34.8)34 (50.0)32 (48.5)0.142
 Fibromyalgiaa77 (37.9)18 (26.1)30 (44.1)29 (43.9)0.043
 Irritable bowel syndromea76 (37.4)16 (23.2)26 (38.2)34 (51.5)0.003
 Seasonal allergies70 (34.5)24 (34.8)20 (29.4)26 (39.4)0.464
 Dyslipidemia64 (31.5)22 (31.9)19 (27.9)23 (34.8)0.689
 Gastroesophageal reflux disease60 (29.6)22 (31.9)17 (25.0)21 (31.8)0.604
 Sleep apnea53 (26.1)15 (21.7)18 (26.5)20 (30.3)0.501
Prescription medication ever taken, n (%)c
 Biologic176 (86.7)
 Nonbiologic DMARD174 (85.7)
 Antidepressant109 (53.7)
 Steroid medication162 (79.8)
 NSAID167 (82.3)
 Opioid pain medication96 (47.3)
 Other pain medication132 (65.0)
 Sleep medication67 (33.0)
 Other58 (28.6)
 None3 (1.5)
  1. a P < 0.05 comparing respondents with time to PsA diagnosis of < 6 months, 6 months to 4 years, and ≥ 5 years
  2. b Extent of psoriasis may be higher due to effects of treatment on reduction of symptom presentation of psoriasis
  3. c Respondents could have selected > 1 option
  4. DMARD disease-modifying antirheumatic drug, NSAID nonsteroidal anti-inflammatory drug, PsA psoriatic arthritis, RAPID3 Routine Assessment of Patient Index Data 3